Organization · Venture Capital
Almaral
Almaral is a venture capital firm based in Europe, specializing in early-stage investments in biotechnology and life sciences. The firm not only provides funding but also offers comprehensive operational support and consulting services to its portfolio companies.
Overview
What Almaral does
What Almaral is
Almaral is a venture capital firm based in Europe, specializing in early-stage investments in biotechnology and life sciences. The firm not only provides funding but also offers comprehensive operational support and consulting services to its portfolio companies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder
- Last reviewed
- March 30, 2026
Official channels
Find Almaral elsewhere
Open the official website or a supported primary organization account.
Capability profile
Almaral as a funder
Investment thesis
Almaral positions itself as a one-stop-shop for growth-minded biotech companies, addressing the gap in angel/early-stage capital in European biotech. Beyond funding, they provide full operational support, making them more of a venture studio hybrid than a pure fund.
Focus narrative
Almaral invests in early-stage biotechnology and life sciences startups located in Europe, typically providing funding ranging from €0.5 million to €1 million. The firm seeks companies with strong teams capable of executing their business plans and emphasizes responsible investing and adherence to Environmental, Social, and Governance (ESG) principles.
Value beyond capital
Almaral adds value to its portfolio companies through comprehensive support, including business and marketing consulting, legal services, risk management, strategic planning, operational function setup, and assistance with early-stage sales and marketing. They also help with commercialization and international expansion.
Terms and economics
- Typical check
- $500,000–$1,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A
- Sectors
- Biotech · Healthcare · Medical Devices
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
MONCYTE Health: Develops innovative diagnostic technology for cardiovascular disease. Orla: Focuses on making primary care more accessible and impactful. Fepod: Specializes in diagnostics and has received extensive support from Almaral. Genomill: Engaged in biotechnology with a focus on product commercialization. Marginum: Provides health technology solutions and has benefited from Almaral's market entry strategies.
Common questions
What to know about Almaral
Upseed classifies Almaral under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.